Lipocine Inc. Files 8-K for Financials and Exhibits
Ticker: LPCN · Form: 8-K · Filed: Dec 11, 2025 · CIK: 1535955
| Field | Detail |
|---|---|
| Company | Lipocine Inc. (LPCN) |
| Form Type | 8-K |
| Filed Date | Dec 11, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-k, financials, exhibits
Related Tickers: LPCN
TL;DR
LPCN filed an 8-K on 12/11 for 12/8 events - mostly financials/exhibits.
AI Summary
Lipocine Inc. filed an 8-K on December 11, 2025, reporting on events that occurred on December 8, 2025. The filing primarily concerns financial statements and exhibits, with no specific material events detailed in the provided text.
Why It Matters
This filing indicates Lipocine Inc. is providing updated financial information and exhibits to the SEC, which is standard procedure but important for investors to review for company health.
Risk Assessment
Risk Level: low — This is a routine filing for financial statements and exhibits, not indicating any immediate material changes or risks.
Key Players & Entities
- Lipocine Inc. (company) — Registrant
- December 8, 2025 (date) — Earliest event reported
- December 11, 2025 (date) — Filing date
- 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108 (location) — Principal executive offices
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The provided text states the filing concerns 'Financial Statements and Exhibits' but does not list the specific documents included.
Are there any material events reported in this 8-K beyond the standard financial disclosures?
The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' with no specific material events detailed in the excerpt.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K was on December 8, 2025.
What is Lipocine Inc.'s principal executive office address?
Lipocine Inc.'s principal executive offices are located at 675 Arapeen Drive, Suite 202, Salt Lake City, Utah 84108.
What is the SEC file number for Lipocine Inc.?
Lipocine Inc.'s SEC file number is 001-36357.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-12-11 17:01:25
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share LPCN The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 1KB
- ex99-2.htm (EX-99.2) — 1KB
- form8-k_001.jpg (GRAPHIC) — 7KB
- ex99-1_001.jpg (GRAPHIC) — 927KB
- ex99-2_001.jpg (GRAPHIC) — 997KB
- 0001493152-25-027273.txt ( ) — 2875KB
- lpcn-20251208.xsd (EX-101.SCH) — 3KB
- lpcn-20251208_lab.xml (EX-101.LAB) — 33KB
- lpcn-20251208_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. The Company presented posters for LPCN 2101 at the American Epilepsy Society (AES) Annual Meeting held December 5 th through the 9 th , 2025 in Atlanta, GA. The posters are furnished as Exhibit 99.1 and 99.2 to this report and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are filed with this report: Exhibit No. Description 99.1 Poster entitled "Clinical Pharmacokinetics and Tolerability of a Novel Oral GABA A Receptor Positive Allosteric Modulating Candidate for Epilepsy" 99.2 Poster entitled "Oral Toxicokinetics of a Bioidentical GABA A Receptor Modulating Neuroactive Steroid Anti-Seizure Medication Candidate for Women with Epilepsy" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIPOCINE INC. Date: December 11, 2025 By: /s/ Mahesh V. Patel Mahesh V. Patel President and Chief Executive Officer